DecisionDx-GBM Gene Expression Assay for Prognostic Testing in Glioblastoma Multiform

It is estimated that approximately 22,000 Americans will be diagnosed with tumor of the brain or nervous system in 2010. Among primary brain tumors, approximately 60% are gliomas, the most common and most malignant of which is glioblastoma multiforme (GBM).The DecisionDx-GBM test is a multigene expr...

Descripción completa

Detalles Bibliográficos
Autores principales: Allingham-Hawkins, Diane, Lea, Andrew, Levine, Susan
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Evidence on Genomic Tests
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957243/
https://www.ncbi.nlm.nih.gov/pubmed/20972474
http://dx.doi.org/10.1371/currents.RRN1186
_version_ 1782188218463027200
author Allingham-Hawkins, Diane
Lea, Andrew
Levine, Susan
author_facet Allingham-Hawkins, Diane
Lea, Andrew
Levine, Susan
author_sort Allingham-Hawkins, Diane
collection PubMed
description It is estimated that approximately 22,000 Americans will be diagnosed with tumor of the brain or nervous system in 2010. Among primary brain tumors, approximately 60% are gliomas, the most common and most malignant of which is glioblastoma multiforme (GBM).The DecisionDx-GBM test is a multigene expression assay that is designed to predict which patients are likely to experience long-term (> 2 years) progression-free survival.
format Text
id pubmed-2957243
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-29572432010-10-20 DecisionDx-GBM Gene Expression Assay for Prognostic Testing in Glioblastoma Multiform Allingham-Hawkins, Diane Lea, Andrew Levine, Susan PLoS Curr Evidence on Genomic Tests It is estimated that approximately 22,000 Americans will be diagnosed with tumor of the brain or nervous system in 2010. Among primary brain tumors, approximately 60% are gliomas, the most common and most malignant of which is glioblastoma multiforme (GBM).The DecisionDx-GBM test is a multigene expression assay that is designed to predict which patients are likely to experience long-term (> 2 years) progression-free survival. Public Library of Science 2010-11-26 /pmc/articles/PMC2957243/ /pubmed/20972474 http://dx.doi.org/10.1371/currents.RRN1186 Text en http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Evidence on Genomic Tests
Allingham-Hawkins, Diane
Lea, Andrew
Levine, Susan
DecisionDx-GBM Gene Expression Assay for Prognostic Testing in Glioblastoma Multiform
title DecisionDx-GBM Gene Expression Assay for Prognostic Testing in Glioblastoma Multiform
title_full DecisionDx-GBM Gene Expression Assay for Prognostic Testing in Glioblastoma Multiform
title_fullStr DecisionDx-GBM Gene Expression Assay for Prognostic Testing in Glioblastoma Multiform
title_full_unstemmed DecisionDx-GBM Gene Expression Assay for Prognostic Testing in Glioblastoma Multiform
title_short DecisionDx-GBM Gene Expression Assay for Prognostic Testing in Glioblastoma Multiform
title_sort decisiondx-gbm gene expression assay for prognostic testing in glioblastoma multiform
topic Evidence on Genomic Tests
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957243/
https://www.ncbi.nlm.nih.gov/pubmed/20972474
http://dx.doi.org/10.1371/currents.RRN1186
work_keys_str_mv AT allinghamhawkinsdiane decisiondxgbmgeneexpressionassayforprognostictestinginglioblastomamultiform
AT leaandrew decisiondxgbmgeneexpressionassayforprognostictestinginglioblastomamultiform
AT levinesusan decisiondxgbmgeneexpressionassayforprognostictestinginglioblastomamultiform

Ejemplares similares